Management of hyperinflammation in COVID-19 patients

Suberviola, Borja; Cuenca Fito, Elena

doi:10.37201/req/s03.02.2022

dc.contributor.author	Suberviola, Borja	es_ES
dc.contributor.author	Cuenca Fito, Elena	es_ES
dc.contributor.other	Universidad de Cantabria	es_ES
dc.date.accessioned	2023-02-24T15:16:17Z
dc.date.available	2023-02-24T15:16:17Z
dc.date.issued	2022	es_ES
dc.identifier.issn	0214-3429	es_ES
dc.identifier.issn	1988-9518	es_ES
dc.identifier.uri	https://hdl.handle.net/10902/27885
dc.description.abstract	In response to SARS-CoV-2 infection, the immune system physiologically upregulates to try to clear the virus from the body; failure to compensate for this inflammatory response with an anti-inflammatory response leads to dysregulation of the immune system that ultimately leads to a situation of uncontrolled hyperinflammation called cytokine storm. This cytokine storm can cause ARDS or multi-organ failure leading to patient death. This review exposes the different mechanisms of the inflammatory response in COVID-19 infection and the therapeutic options to treat this process.	es_ES
dc.format.extent	4 p.	es_ES
dc.language.iso	eng	es_ES
dc.publisher	Sociedad española de quimioterapia	es_ES
dc.rights	Attribution 4.0 International	*
dc.rights	©The Author 2022. Published by Sociedad Española de Quimioterapia	es_ES
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/	*
dc.source	Revista Española de Quimioterapia 2022; 35 (Suppl. 3): 6-9	es_ES
dc.subject.other	COVID19	es_ES
dc.subject.other	Corticosteroids	es_ES
dc.subject.other	Tocilizumab	es_ES
dc.subject.other	Immunomodulators	es_ES
dc.title	Management of hyperinflammation in COVID-19 patients	es_ES
dc.type	info:eu-repo/semantics/article	es_ES
dc.relation.publisherVersion	https://doi.org/10.37201/req/s03.02.2022	es_ES
dc.rights.accessRights	openAccess	es_ES
dc.identifier.DOI	10.37201/req/s03.02.2022	es_ES
dc.type.version	publishedVersion	es_ES